ModernaTX Gains FDA Approval for MNEXSPIKE mRNA COVID-19 Vaccine Under STN 125835

ModernaTX, Inc. has secured FDA biologics licensure for MNEXSPIKE (COVID-19 Vaccine, mRNA) under STN 125835, adding a licensed mRNA product to the COVID-19 vaccine portfolio with a defined indication that restricts use to adults 65 and older and to individuals aged 12 through 64 carrying at least one high-risk underlying condition. For biologics manufacturers and QA directors tracking the mRNA platform's regulatory trajectory, the approval documents a complete licensure pathway rather than an Emergency Use Authorization, with implications for comparability, lot release, and post-market commitments.

The regulatory record is unusually layered. An initial Approval Letter dated May 30, 2025 was followed by a Center Director Override Memo on the same date, a second Approval Letter issued July 3, 2025, and a third Approval Letter dated August 27, 2025, accompanied by a Center Director Decisional Memo on August 26, 2025. A Chair Review Memorandum followed on September 26, 2025. That sequence signals iterative agency review activity post-initial approval, a pattern QA and regulatory affairs leads should examine closely when assessing their own BLA lifecycle management and post-approval change strategies.

The approved indication is population-specific: MNEXSPIKE is not authorized for broad use across all age groups. Individuals 65 years and older qualify unconditionally; those aged 12 through 64 must present at least one qualifying underlying condition associated with high risk for severe COVID-19 outcomes. Manufacturers producing vaccines or biologics under similar population-stratified indications should note how labeling precision at the indication level intersects with 21 CFR Part 601 licensure standards and post-market surveillance obligations.

Supporting documentation published to the FDA biologics portal includes the Summary Basis for Regulatory Action dated May 30, 2025, the full Package Insert, a Patient Package Insert, and Demographic Subgroup Information with a specific reference to Section 1.1 of the Clinical Review Memo for subgroup outcome analysis. Regulatory affairs teams preparing BLA submissions or managing licensed mRNA products should treat the SBRA and the Clinical Review Memo as primary reference documents for understanding the evidentiary standard applied at licensure.

The multi-letter approval sequence for MNEXSPIKE, spanning May through September 2025, will serve as a reference case for how FDA manages iterative post-approval decisions on mRNA biologics under full licensure conditions.

Source: FDA Vaccines, Blood and Biologics portal via What's New Vaccines Blood Biologics RSS Feed, 2026-06-04.